Teijin Limited
6-7, Minami Hommachi 1-chome, Chuo-ku
Osaka
541-8587
Tel: 81-6-6268-2132
Fax: 81-6-6268-3205
Website: http://www.teijin.co.jp
27 articles about Teijin Limited
-
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
11/29/2023
Ascendis Pharma A/S announced that the company has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan.
-
electroCore Announces Exclusive License Agreement with Teijin for Japan Territory
4/5/2022
electroCore, Inc. announced it has entered into an agreement with Teijin Limited, a global conglomerate based in Japan offering advanced solutions in the fields including healthcare, material and information technology, to license certain exclusive rights to its non-invasive vagus nerve stimulation technology for commercialization in Japan for a range of primary headache disorders.
-
Teijin and NeuroSigma Enter into Exclusive License Agreement
10/17/2019
Teijin Pharma to Market eTNS for the Treatment of ADHD in JaAs part of the agreement, Teijin Pharma will seek regulatory approval in Japan for the Monarch eTNS System (Monarch) for the treatment of ADHD.pan
-
Clinical Trial of New Cardiovascular Patch Launched
6/26/2019
Osaka Medical College, Fukui Tateami Co., Ltd. and Teijin Limited announced that the alliance has launched a clinical trial of their newly developed patch material, OFT-G1, for cardiovascular surgery and the first surgery using the OFT-G1 was successfully performed.
-
Teijin Establishes Nutraceutical Product Firm for Productive Aging
5/16/2019
Teijin Limited announced today its establishment of NOMON, Co., Ltd. to sell nutraceutical food and beverages that are scientifically proven to help people maintain their health.
-
Teijin and AMED Sign R&D Consignment Agreement to Develop Drugs for Frail
5/14/2019
Teijin Limited announced today that it has signed a research and development agreement with the Japan Agency for Medical Research and Development (AMED) to form an industry-government-academia partnership that will explore preventive and therapeutic drugs for frail elderly people as designated under AMED’s Cyclic Innovation for Clinical Empowerment program(CiCLE) in October 2018.
-
SanBio and Teijin to Terminate Licensing Agreement regarding SB623 for Stroke Treatment
2/14/2018
SanBio and Teijin Limited jointly announced today that they would terminate the exclusive licensing agreement signed in 2009 regarding the development and marketing of SB623 for stroke treatment in Japan.
-
Teijin to Boost Production of MIRAIM High-Performance Microporous Membrane
2/6/2018
The company will invest around JPY 3 billion on the expansion, targeting operations expected to begin in early 2019.
-
Teijin Acquires Exclusive Sales Rights To Transcranial Magnetic Stimulation Device In Japan
10/16/2017
Teijin Pharma Limited announced today that it has acquired the exclusive sales rights in Japan to the NeuroStar Transcranial Magnetic Stimulation (TMS) for treating depression that does not respond well to normal antidepressant drug-based therapies.
-
Merz Pharma GmbH & Co. KGaA And Teijin Limited Announce Partnership To Bring Xeomin (Incobotulinumtoxina) To Japan
10/12/2017
-
JCR Pharmaceuticals And Teijin Limited To Develop Allogeneic Regenerative Medical Product Using Dental Pulp Stem Cells (DPCs)
7/18/2017
-
Radius Health Announces License And Development Agreement For Abaloparatide-SC With Teijin Limited In Japan
7/13/2017
-
Teijin Limited To Withdraw From U.S. Home Health Care Business To Complete Business Restructuring
4/28/2017
-
Teijin Limited To Exhibit At Techtextil 2017 In Frankfurt
4/25/2017
-
Teijin Limited To Participate In ISPO Munich
1/30/2017
-
Bay Area's Versartis Strikes $165 Million Growth Hormone Deal With Teijin Limited
8/10/2016
-
Teijin Limited Receives Life Nanotechnology Award At Nano Tech 2016
2/16/2016
-
Teijin Limited Signs Sales Agreement For New Anti-inflammatory Analgesic Patch Formulation
4/1/2015
-
Nakashima And Teijin Limited To Establish Joint Venture For Global Expansion Of Japanese-Made Medical Device Business
2/23/2015
-
Teijin Limited Release: Small-sized MUCOSOLVAN L Expectorant Tablet 45 Mg Approved In Japan
2/16/2015